Hologic to buy Focal Therapeutics

By AuntMinnie.com staff writers

September 27, 2018 -- Women's imaging firm Hologic is planning to acquire Focal Therapeutics, the developer of an implantable 3D marker to mark tumor excision sites during lumpectomy procedures.

Hologic plans to pay $125 million for the privately held company, which it will add to its Breast Health product portfolio. Focal Therapeutics generated about $16 million in revenue over the past 12 months.

Focal Therapeutics makes BioZorb, a 3D marker placed by surgeons to mark excision sites for monitoring and future treatments. BioZorb has an open design that allows for tissue in-growth during the healing process, according to Hologic.

Copyright © 2018 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking